Abstract Library

#3417 SARS-CoV-2 vaccination site as possible pitfall on somatostatin receptor imaging

Introduction: SARS-CoV-2 (COVID19) vaccinations have shown high efficacy. Therefore, increased chances exist that patients undergoing Peptide Receptor Radionuclide Therapy (PRRT) or radionuclide imaging for Neuroendocrine Tumors (NETs) may have being recently vaccinated.

Conference:

Presenting Author: Kolade O

Authors: Kolade O, Ayeni A, Brink A, Steyn R, Prasad V,

Keywords: COVID-19, SARS-CoV-2, Lu-177 DOTATATE, Ga-68 DOTANOC, Vaccination, PRRT, Neuroendocrine Tumor,

#3338 Utility of SSTR radioligands in imaging and treatment of paediatric GEP-NETs

Introduction: Metastasized gastroenteropancreatic neuroendocrine tumors (GEP-NETS) in paediatric patients

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Steyn R

Authors: Steyn R, Kolade O, Aldera A, Masoka B, Radebe B,

Keywords: SSTR, PRRT, paediatric, GEP-NET,

#2230 Does Somatostatin Receptor (SSR) Positive Tumor Volume Determined on Ga68 DOTANOC PET/CT in Patients with Paraganglioma (PGL)/Pheochromocytoma(PCC) Correlate with Biomarkers? An Explorative Study

Introduction: SSR PET/CT is used in workup of pts with PCC/ PGL. Correlation of tumour burden on PET & biomarkers 24 hr Urine Metanephrines (UMET), normetanephrine (UNMET), UMET:creatinine ratio (MET:Crea),UNMET:creatinine (UNMET:crea) & Chromogranin A (CGA) has not been done.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Steyn R

Authors: Steyn R, Prasad V,

Keywords: 68Ga DOTANOC PET CT, PGL, PCC,

#1833 Peptide Receptor Radionuclide Therapy in a Patient with SDHB Related Grade 3 Paraganglioma (PGL) of Urinary Bladder

Introduction: SDHB mutation cause aggressive metastatic PGL.36% of patients survive 5 yrs,treatment options are limited & many still being evaluated

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Steyn R, Prasad V,

Keywords: SDHB, Bladder PGL, PRRT ,